Document is current
Any future updates will be listed below
-
Authors
Khedro, Tarek
Attias, Jennifer
Eshraghian, Emily
Tsotras, Melina
Margolin, Emily
Yassin, Shaden
Silver, Elizabeth
Bui, Quan
Borooah, Shyamanga
Laverty, Chamindra G.
Taylor, Matthew R. G.
Adler, Eric D.
Hong, Kimberly N. https://orcid.org/0000-0003-3293-138X
-
Funding
Funding for this research was provided by:
Rocket (Rocket)
- License Information
-
More Information
Article History
Received: 21 June 2024
Accepted: 20 September 2025
First Online: 21 October 2025
Declarations
:
: Include a statement on ethics approval and consent (even where the need for approval was waived). Include the name of the ethics committee that approved the study and the committee’s reference number if appropriate.
: Not applicable.
: EDA declares that he is consulting for Abiomed, Novartis, Abbott, Ionis Pharmaceuticals, Sana Biotechnology, Medtronic, Lexeo Pharmaceuticals, Cytokinetics, and Endotronics. He also reports Papillion Therapeutics (Founder and Board Member) and ResQ Pharmaceuticals (Scientific Advisory Board); he is a Shareholder for Rocket Pharmaceuticals; and he was an expert witness for AstraZeneca. QB is a consultant for EcoR1 and Lexeo Therapeutics. CGL declares that she is consulting for Sarepta Therapeutics, Dyne Therapeutics, Avidity Biosciences, Catalyst, Biogen, and Novartis. KNH, TK, ES, JA, SY, MRGT declare that they have no competing interests.
